BNTC - Benitec Biopharma Limited Stock Price, News & Analysis

$2.61 0.02 (0.77 %)
(As of 11/22/2017 03:04 PM ET)
Previous Close$2.59
Today's Range$2.58 - $2.61
52-Week Range$1.30 - $5.48
Volume17,800 shs
Average Volume302,173 shs
Market Capitalization$26.77 million
P/E RatioN/A
Dividend YieldN/A
Beta3.44

About Benitec Biopharma Limited (NASDAQ:BNTC)

Benitec Biopharma Limited logoBenitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:BNTC
  • CUSIP: N/A
  • Web: www.benitec.com
Debt:
  • Current Ratio: 19.88%
  • Quick Ratio: 19.88%
Sales & Book Value:
  • Annual Sales: $8.36 million
  • Price / Sales: 3.20
  • Book Value: $1.58 per share
  • Price / Book: 1.65
Profitability:
  • Net Income: $-4,280,000.00
  • Net Margins: -50.76%
  • Return on Equity: -26.97%
  • Return on Assets: -25.55%
Misc:
  • Employees: 18
  • Outstanding Shares: 10,260,000
 

Frequently Asked Questions for Benitec Biopharma Limited (NASDAQ:BNTC)

What is Benitec Biopharma Limited's stock symbol?

Benitec Biopharma Limited trades on the NASDAQ under the ticker symbol "BNTC."

When will Benitec Biopharma Limited make its next earnings announcement?

Benitec Biopharma Limited is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Benitec Biopharma Limited.

Who are some of Benitec Biopharma Limited's key competitors?

Who are Benitec Biopharma Limited's key executives?

Benitec Biopharma Limited's management team includes the folowing people:

  • Gregory West, Chief Executive Officer, Company Secretary
  • Bryan Dulhunty, Chief Financial Officer
  • Clifford Michael Holloway, Chief Business and Operating Officer (Age 57)
  • Michael Graham, Chief Scientific Officer
  • Jerel A. Banks M.D., Ph.D., Non-Executive Chairman of the Board
  • Kevin Buchi CPA, Director
  • Megan Joan Boston, Non-Executive Director
  • Peter Damian Francis, Non-Executive Director

When did Benitec Biopharma Limited IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

How do I buy Benitec Biopharma Limited stock?

Shares of Benitec Biopharma Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Benitec Biopharma Limited's stock price today?

One share of Benitec Biopharma Limited stock can currently be purchased for approximately $2.61.

How big of a company is Benitec Biopharma Limited?

Benitec Biopharma Limited has a market capitalization of $26.77 million and generates $8.36 million in revenue each year. Benitec Biopharma Limited employs 18 workers across the globe.

How can I contact Benitec Biopharma Limited?

Benitec Biopharma Limited's mailing address is SE 1201 99 Mount St, NORTH SYDNEY, NSW 2060, Australia. The biotechnology company can be reached via phone at +61-2-95556986 or via email at [email protected]


MarketBeat Community Rating for Benitec Biopharma Limited (BNTC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about Benitec Biopharma Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Benitec Biopharma Limited (NASDAQ:BNTC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Benitec Biopharma Limited (NASDAQ:BNTC)

Price Target History for Benitec Biopharma Limited (NASDAQ:BNTC)

Analysts' Ratings History for Benitec Biopharma Limited (NASDAQ:BNTC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/30/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History for Benitec Biopharma Limited (NASDAQ:BNTC)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Benitec Biopharma Limited (NASDAQ:BNTC)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Benitec Biopharma Limited (NASDAQ:BNTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Benitec Biopharma Limited (NASDAQ BNTC)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Benitec Biopharma Limited (NASDAQ BNTC)

Source:
DateHeadline
U.S. patent granted for Benitec hepatitis B programU.S. patent granted for Benitec hepatitis B program
finance.yahoo.com - October 18 at 5:59 PM
Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017
finance.yahoo.com - September 5 at 6:16 PM
Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017
finance.yahoo.com - September 1 at 4:55 PM
Benitec Biopharma Limited (BNTC) Earns "Hold" Rating from Maxim GroupBenitec Biopharma Limited (BNTC) Earns "Hold" Rating from Maxim Group
www.americanbankingnews.com - August 30 at 11:20 AM
Benitec Biopharma advances OPMD orphan disease programBenitec Biopharma advances OPMD orphan disease program
finance.yahoo.com - August 8 at 4:23 PM
Mid-Day Market Update: Shutterfly Drops On Downbeat Earnings; Mead Johnson Shares Spike HigherMid-Day Market Update: Shutterfly Drops On Downbeat Earnings; Mead Johnson Shares Spike Higher
www.benzinga.com - February 2 at 9:14 PM
Mid-Afternoon Market Update: Weatherford Rises Following Q4 Results; Ralph Lauren Shares PlungeMid-Afternoon Market Update: Weatherford Rises Following Q4 Results; Ralph Lauren Shares Plunge
www.nasdaq.com - February 2 at 4:09 PM
Benitec Biopharma (BNTC) Gains After Announces Progress on ddRNAi TechnologyBenitec Biopharma (BNTC) Gains After Announces Progress on ddRNAi Technology
www.streetinsider.com - February 2 at 4:09 PM
Tuesday’s Top Biopharma MoversTuesday’s Top Biopharma Movers
247wallst.com - January 19 at 5:03 PM
Benitec Biopharma (BNTC) Leaped After European Orphan Drug DesignationBenitec Biopharma (BNTC) Leaped After European Orphan Drug Designation
www.rttnews.com - January 19 at 5:03 PM
Benitec Receives Orphan Drug Designation in the...Benitec Receives Orphan Drug Designation in the...
www.benzinga.com - January 18 at 3:24 PM
Benitec Biopharma (BNTC) BB-301 Granted Orphan Drug Designation in EUBenitec Biopharma (BNTC) BB-301 Granted Orphan Drug Designation in EU
www.streetinsider.com - January 18 at 3:24 PM
Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular DystrophyBenitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy
us.rd.yahoo.com - January 17 at 9:32 AM
Benitec in-licenses clinical program for head and neck cancer from NantWorksBenitec in-licenses clinical program for head and neck cancer from NantWorks
us.rd.yahoo.com - December 23 at 4:07 PM
7:13 am Benitec Biopharma in-licenses clinical program for head and neck cancer from NantWorks; financial terms not disclosed7:13 am Benitec Biopharma in-licenses clinical program for head and neck cancer from NantWorks; financial terms not disclosed
us.rd.yahoo.com - December 23 at 4:07 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Benitec Biopharma Limited (NASDAQ BNTC) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.